title: Optimal duration of trastuzumab for early HER2-positive breast cancer.
authors.affiliation: Department of Medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Specht
authors.affiliation: Department of Medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. Electronic address: ndavidson@fredhutch.org.
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
mesh_terms: D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab